Home>Topics>Stocks>NPS Pharmaceuticals

NPS Pharmaceuticals NPSP

  1. All
  2. Commentary
  3. Headlines
    1. NPS Pharmaceuticals : The Small Bio-Tech You Should Not Be Ignoring With 30% Upside


      Mon, 21 Jul 2014

      By Benjamin Livingston : NPS Pharmaceuticals (NASDAQ: NPSP ) is a biopharmaceutical that ..... With this strategy in mind, NPSP develops drugs that will, in ..... company has to offer. In addition, NPSP receives royalties from numerous

    2. Consider Shire Pharmaceuticals Now; 20%+ Upside Left In Takeover Bid By AbbVie


      Mon, 30 Jun 2014

      By Dr. Paul Nunzio De Santis, Pharm.D : Please see Shire's website here for LSE to ADR share conversion methodology. Investment Thesis With SHPG trading currently at ~21x 2015E and ample capacity to grow through acquisitions, we expect SHPG to preserve its current takeover premium through the July

    3. FDA approves updated labeling for Gattex


      Mon, 30 Jun 2014

      The U.S. regulator approves new labeling for NPS Pharmaceuticals ' ( NPSP ) Gattex ( teduglutide [rDNA origin]) for injection to include long-term data from the STEPS 2 clinical trial of adult patients

    4. Shire's Potential Offer For NPS Pharma Is Too Low


      Wed, 11 Jun 2014

      By ONeil Trader : NPS Pharma ( NPSP ) has been a victim of a vicious sell-off in the biotech sector ( IBB ), but the stock is now 50% higher than it was a month

    5. Sell-Off in Health Care Sector Overlooks Strong Fundamentals


      Fri, 25 Apr 2014

      Pharmaceuticals International, Inc. (U.S. Shares) (2.19%), AstraZeneca PLC (ADR) (1.78%) and NPS Pharmaceuticals , Inc. (1.74%). There are no assurances that any Janus portfolio currently holds these securities or other

    6. FDA staff says NPS Pharma's bowel drug needs no safety restrictions


      Fri, 12 Oct 2012

      (Reuters) - U.S. drug reviewers found three serious concerns related to NPS Pharmaceuticals Inc's experimental drug for short bowel syndrome but said they did not think the drug needed to be...

    « Prev1234Next »
    Content Partners